Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

被引：97

作者：

Bardotti, Angela ^{[1
]}

Averani, Giovanni ^{[1
]}

Berti, Francesco ^{[1
]}

Berti, Stefania ^{[1
]}

Carinci, Valeria ^{[1
]}

D'Ascenzi, Sandro ^{[1
]}

Fabbri, Barbara ^{[1
]}

Glannini, Sara ^{[1
]}

Giannozzi, Aldo ^{[1
]}

Magagnoli, Claudia ^{[1
]}

Proietti, Daniela ^{[1
]}

Norelli, Francesco ^{[1
]}

Rappuoli, Rino ^{[1
]}

Ricci, Stefano ^{[1
]}

Costantino, Paolo ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost Srl, I-53100 Siena, Italy

来源：

VACCINE | 2008年 / 26卷 / 18期

关键词：

glycoconjugate vaccines; physicochemical characterisation; Neisseria meningitidis;

D O I：

10.1016/j.vaccine.2008.01.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bacterial capsular polysaccharides covalently linked to an appropriate carrier protein represent the best tool. to induce a protective immune response against a wide range of bacterial diseases, such as meningococcal infections. We describe here the physico-chemical characterisation of glycoconjugate molecules designed to prepare a vaccine against Neisseria meningitidis serogroups A, C, W135 and Y. The use of a selective conjugation chemistry resulted in well. characterised, reproducible and traceable glycoconjugate that can be consistently manufactured at large scale. A pool of physical and spectroscopic methods was used to establish glycosylation ratio, identity, molecular weight profiles, integrity of carrier protein and sites of glycosylation, assuring effective and consistent lots of vaccines. (C) 2008 Published by Elsevier Ltd.

引用

页码：2284 / 2296

页数：13

共 50 条

[21] Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines
Tontini, M.
Berti, F.
Romano, M. R.
Proietti, D.
Zambonelli, C.
Bottomley, M. J.
De Gregorio, E.
Del Giudice, G.
Rappuoli, R.
Costantino, P.
Brogioni, G.
Balocchi, C.
Biancucci, M.
Malito, E.
[J]. VACCINE, 2013, 31 (42) : 4827 - 4833
[22] Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines
Poland, Gregory A.
[J]. CLINICAL INFECTIOUS DISEASES, 2010, 50 : S45 - S53
[23] One disease, two vaccines: challenges in prevention of meningococcal disease
Patel, Cyra
Chiu, Clayton K.
Beard, Frank H.
Crawford, Nigel W.
Macartney, Kristine
[J]. MEDICAL JOURNAL OF AUSTRALIA, 2020, 212 (10) : 453 - +
[24] MENINGITIS AND ITS PREVENTION BY POLYOSIDIC ANTI-MENINGOCOCCAL VACCINES
GALAZKA, A
[J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 1982, 60 (03): : 305 - 312
[25] Meningococcal vaccines
Knuf, M.
Tenenbaum, T.
[J]. MONATSSCHRIFT KINDERHEILKUNDE, 2021, 169 (11) : 1034 - 1042
[26] Meningococcal vaccines
Rüggeberg J.U.
Pollard A.J.
[J]. Pediatric Drugs, 2004, 6 (4) : 251 - 266
[27] Meningococcal vaccines
Rosenstein, NE
Fischer, M
Tappero, JW
[J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2001, 15 (01) : 155 - +
[28] MENINGOCOCCAL VACCINES
不详
[J]. CLINICAL PEDIATRICS, 1985, 24 (11) : 622 - 622
[29] Meningococcal Vaccines
Price, Alicia A.
[J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (19) : 2009 - 2014
[30] Meningococcal Vaccines
Ozdemir, Halil
Ciftci, Ergin
[J]. JOURNAL OF PEDIATRIC INFECTION, 2014, 8 (04): : 178 - 186

← 1 2 3 4 5 →